Share-based Payment Arrangement, Expense of Arcus Biosciences, Inc. from 31 Mar 2017 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Arcus Biosciences, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Mar 2017 to 30 Sep 2025.
  • Arcus Biosciences, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $14,000,000, a 26% decline year-over-year.
  • Arcus Biosciences, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $62,000,000, a 19% decline year-over-year.
  • Arcus Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $76,000,000, a 4.1% increase from 2023.
  • Arcus Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $73,000,000, a 12% increase from 2022.
  • Arcus Biosciences, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $65,000,000, a 18% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Arcus Biosciences, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $62,000,000 $14,000,000 -$5,000,000 -26% 01 Jul 2025 30 Sep 2025 10-Q 28 Oct 2025 2025 Q3
Q2 2025 $67,000,000 $15,000,000 -$5,000,000 -25% 01 Apr 2025 30 Jun 2025 10-Q 06 Aug 2025 2025 Q2
Q1 2025 $72,000,000 $16,000,000 -$4,000,000 -20% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $76,000,000 $17,000,000 -$1,000,000 -5.6% 01 Oct 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
Q3 2024 $77,000,000 $19,000,000 +$1,000,000 +5.6% 01 Jul 2024 30 Sep 2024 10-Q 28 Oct 2025 2025 Q3
Q2 2024 $76,000,000 $20,000,000 +$2,000,000 +11% 01 Apr 2024 30 Jun 2024 10-Q 06 Aug 2025 2025 Q2
Q1 2024 $74,000,000 $20,000,000 +$1,000,000 +5.3% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $73,000,000 $18,000,000 +$1,000,000 +5.9% 01 Oct 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
Q3 2023 $72,000,000 $18,000,000 +$2,000,000 +12% 01 Jul 2023 30 Sep 2023 10-Q 06 Nov 2024 2024 Q3
Q2 2023 $70,000,000 $18,000,000 +$3,000,000 +20% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $67,000,000 $19,000,000 +$2,000,000 +12% 01 Jan 2023 31 Mar 2023 10-Q 08 May 2024 2024 Q1
Q4 2022 $65,000,000 $17,000,000 +$2,713,000 +19% 01 Oct 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
Q3 2022 $62,287,000 $16,000,000 +$1,415,000 +9.7% 01 Jul 2022 30 Sep 2022 10-Q 07 Nov 2023 2023 Q3
Q2 2022 $60,872,000 $15,000,000 +$1,633,000 +12% 01 Apr 2022 30 Jun 2022 10-Q 07 Aug 2023 2023 Q2
Q1 2022 $59,239,000 $17,000,000 +$4,239,000 +33% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q4 2021 $55,000,000 $14,287,000 +$6,221,000 +77% 01 Oct 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
Q3 2021 $48,779,000 $14,585,000 +$8,583,000 +143% 01 Jul 2021 30 Sep 2021 10-Q 02 Nov 2022 2022 Q3
Q2 2021 $40,196,000 $13,367,000 +$8,897,000 +199% 01 Apr 2021 30 Jun 2021 10-Q 03 Aug 2022 2022 Q2
Q1 2021 $31,299,000 $12,761,000 +$9,299,000 +269% 01 Jan 2021 31 Mar 2021 10-Q 09 May 2022 2022 Q1
Q4 2020 $22,000,000 $8,066,000 01 Oct 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
Q3 2020 $6,002,000 +$3,262,000 +119% 01 Jul 2020 30 Sep 2020 10-Q 08 Nov 2021 2021 Q3
Q2 2020 $4,470,000 +$2,340,000 +110% 01 Apr 2020 30 Jun 2020 10-Q 05 Aug 2021 2021 Q2
Q1 2020 $3,462,000 +$1,788,000 +107% 01 Jan 2020 31 Mar 2020 10-Q 05 May 2021 2021 Q1
Q3 2019 $2,740,000 +$1,692,000 +161% 01 Jul 2019 30 Sep 2019 10-Q 05 Nov 2020 2020 Q3
Q2 2019 $2,130,000 +$1,014,000 +91% 01 Apr 2019 30 Jun 2019 10-Q 06 Aug 2020 2020 Q2
Q1 2019 $1,674,000 +$1,018,000 +155% 01 Jan 2019 31 Mar 2019 10-Q 05 May 2020 2020 Q1
Q3 2018 $1,048,000 +$912,000 +671% 01 Jul 2018 30 Sep 2018 10-Q 05 Nov 2019 2019 Q3
Q2 2018 $1,116,000 +$985,000 +752% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $656,000 +$584,000 +811% 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1
Q3 2017 $136,000 01 Jul 2017 30 Sep 2017 10-Q 08 Nov 2018 2018 Q3
Q2 2017 $131,000 01 Apr 2017 30 Jun 2017 10-Q 06 Aug 2018 2018 Q2
Q1 2017 $72,000 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1

Arcus Biosciences, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $76,000,000 +$3,000,000 +4.1% 01 Jan 2024 31 Dec 2024 10-K 25 Feb 2025 2024 FY
2023 $73,000,000 +$8,000,000 +12% 01 Jan 2023 31 Dec 2023 10-K 25 Feb 2025 2024 FY
2022 $65,000,000 +$10,000,000 +18% 01 Jan 2022 31 Dec 2022 10-K 25 Feb 2025 2024 FY
2021 $55,000,000 +$33,000,000 +150% 01 Jan 2021 31 Dec 2021 10-K 21 Feb 2024 2023 FY
2020 $22,000,000 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.